



October 29, 2025

To

The National Stock Exchange of India Limited

Exchange Plaza, 5<sup>th</sup> Floor, Plot No. C/1, G Block,

Bandra-Kurla Complex, Bandra (East),

Mumbai - 400 051

Department of Corporate Services/Listing

**BSE** Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Fort, Mumbai – 400 001

NSE Symbol: APOLLOPIPE SCRIP Code: 531761

Dear Sir/Madam,

Sub: Monitoring Agency Report as per Regulation 32 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for the quarter & half year ended September, 30, 2025

Pursuant to Regulation 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. SEBI/HO/CFD/PoD2/CIR/P/0155 dated November 11, 2024, please find enclosed herewith the Monitoring Agency report issued by CARE Ratings Limited (Monitoring Agency) on the use of proceeds raised through Preferential Issue of Convertible warrants duly reviewed and approved by Audit Committee in its meeting held on October 29, 2025.

Kindly take the above information on your records.

Thanking you

Yours faithfully,

For Apollo Pipes Limited

Gourab Kumar Nayak Company Secretary & Compliance Officer

Encl: A/a



No. CARE/NRO/GEN/2025-26/1101

Mr. Ajay Jain **Chief Financial Officer Apollo Pipes Limited** 37, Hargobind Enclave Vikas Marg, Karkadooma, Delhi,110092

October 29, 2025

Dear Sir,

# Monitoring Agency Report for the quarter ended September 30, 2025 - in relation to the Preferential Issue of Apollo Pipes Limited ("the Company")

We write in our capacity of Monitoring Agency for the Preferential Issue for the amount aggregating to Rs. 110.00 crore of the Company and refer to our duties cast under Regulation 162A of the Securities & Exchange Board of India (Issue of Capital & Disclosure Requirements) Regulations, 2018

In this connection, we are enclosing the Monitoring Agency Report for the quarter ended September 30, 2025 as per aforesaid SEBI Regulations and Monitoring Agency Agreement dated January 27, 2025.

Request you to kindly take the same on records.

Thanking you, Yours faithfully,

**Anant Agarwal** 

Associate Director

Anant.agarwal@careedge.in

Anant Agarwal



# **Report of the Monitoring Agency**

Name of the issuer: Apollo Pipes Limited For quarter ended: September 30, 2025

Name of the Monitoring Agency: CARE Ratings Limited

(a) Deviation from the objects: Nil(b) Range of Deviation: Nil

### **Declaration:**

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit related analyses. We confirm that there is no conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer, or while undertaking credit rating or other commercial transactions with the entity.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

Signature:

Name and designation of the Authorized Signatory: Anant Agarwal Designation of Authorized person/Signing Authority: Associate Director

Anant Agarwal



# 1) Issuer Details:

Name of the issuer : Apollo Pipes Limited

: Mr. Sameer Gupta and Mrs. Meenakshi Gupta Name of the promoter

: The Company manufactures varieties of cPVC, uPVC, and HDPE pipes & fittings, water Industry/sector to which it belongs

storage tanks, PVC taps, fittings and solvents, etc

2) Issue Details

Issue Period : 18 months from date of allotment Type of issue : Preferential issue of Warrants

Type of specified securities : Warrants convertible into equity shares

IPO Grading, if any : Not applicable Issue size (in `crore) : Rs.110.00 crore

# 1) Details of the arrangement made to ensure the monitoring of issue proceeds:

| Particulars   | Reply          | Source of information /<br>certifications considered<br>by Monitoring Agency for<br>preparation of report | Comments of the<br>Monitoring Agency  | Comments of the<br>Board of Directors |
|---|----------------|---|---|---------------------------------------|
| Whether all utilization is as per the disclosures in the Offer Document?  | Yes            | CA Certificate*, Bank<br>Statement and Special<br>Resolution dated February<br>26 <sup>th</sup> 2025      | During Q2FY26 Company incurred Rs. 16.47 crores towards capital expenditure which is one of the stated objects as per the offer document. | No Comments received                  |
| Whether shareholder approval has been obtained in case of material deviations# from expenditures disclosed in the Offer Document? | Not applicable | Management Undertaking  | Not applicable  | No Comments received                  |
| Whether the means of finance for the disclosed objects of the issue have changed?   | No             | Management Undertaking  | Nil   | No Comments received                  |
| Is there any major deviation observed over the earlier monitoring agency reports?   | No             | CA Certificate*, Bank<br>Statements   | No deviations in the earlier monitoring agency report   | No Comments received                  |

# **CARE Ratings Limited**

9th floor, C-001/A2, Berger Towers, Sector 16B, Gautam Budh Nagar, Uttar Pradesh -201301

Phone: +91-120-4452000

Mumbai - 400 022 Phone: +91-22-6754 3456

Email: care@careedge.in • www.careedge.in

CIN-L67190MH1993PLC071691

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East),



| Particulars  | Reply | Source of information /<br>certifications considered<br>by Monitoring Agency for<br>preparation of report | Comments of the<br>Monitoring Agency  | Comments of the<br>Board of Directors |
|--|-------|---|---|---------------------------------------|
| Whether all Government/statutory approvals related to the object(s) have been obtained?                  | Yes   | Management Undertaking  | Nil   | No Comments received                  |
| Whether all arrangements pertaining to technical assistance/collaboration are in operation?              | Yes   | Management Undertaking  | Nil   | No Comments received                  |
| Are there any favorable/unfavorable events affecting the viability of these object(s)?                   | No    | Ctool Evolungo  | Nil   | No Comments received                  |
| Is there any other relevant information that may materially affect the decision making of the investors? | Yes   | Stock Exchange, Management Undertaking, Bank Statement, annual report, Quarterly Results, Note 1          | The CMP of shares of the company is ~Rs. 325.00 as against the warrant issue price of Rs. 550.00 per share. | No Comments received                  |

<sup>\*</sup>CA certificate from Vaps & Company dated October 17, 2025

#Where material deviation may be defined to mean:

Note 1- The warrant proceeds have been earmarked for two primary objectives i.e. towards capital expenditure for the Dadri brownfield expansion and Varanasi greenfield project and towards working capital requirements to support business operations post-expansion. As of date, the Dadri Project is already in operation from July'25. Further, Varanasi project is expected to be commissioned by March'26. Varanasi project is progressing as per schedule timeline with no cost or time overrun.

\*\* The company reported TOI of ~Rs. 1182 crores in FY25 (PY: Rs. 989 crores). Operating margins witnessed decline due to weaker demand in both private real estate and government infrastructure demands as well as higher competitive intensity. During Q1 FY26 company reported TOI of ~Rs. 275 crores (Q1 FY25: Rs. 308 crores) with operating margins at 7.52%.

# 2) Details of objects to be monitored:

(i) Cost of objects -

|           |   | Source of information /  |   |                              |                                      | Comments of the Board of Directors |                           |   |
|-----------|---|--|---|------------------------------|--------------------------------------|------------------------------------|---------------------------|---|
| Sr.<br>No | Item Head   | certifications considered<br>by Monitoring Agency for<br>preparation of report | (as per the<br>Offer<br>Document) in<br>Rs. Crore | Revised Cost in<br>Rs. Crore | Comments of the<br>Monitoring Agency | Reason for cost revision           | Proposed financing option | Particulars of<br>-firm<br>arrangements<br>made |
| 1         | Capital Expenditure for future expansion of existing products | Chartered Accountant   | 33.00   | NA                           | NA                                   | No Comments received               | No Comments received      | No Comments received                            |

## **CARE Ratings Limited**

9th floor, C-001/A2, Berger Towers, Sector 16B, Noida, Gautam Budh Nagar, Uttar Pradesh -201301

Phone: +91-120-4452000

igar, Uttar Pradesh -201301 1452000

CIN-L67190MH1993PLC071691

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai - 400 022

Phone: +91-22-6754 3456

a) Deviation in the objects or purposes for which the funds have been raised

b) Deviation in the amount of funds actually utilized by more than 10% of the amount projected in the offer documents.



|       | and other allied products as may<br>be decided by the board within<br>the tentative timeline of the<br>utilization | AGM Resolution copy   |        |    |    |                      |                         |                         |
|-------|--|---|--------|----|----|----------------------|-------------------------|-------------------------|
| 2     |  | Chartered Accountant<br>certificate*, Bank statements,<br>AGM Resolution copy | 77.00  | NA | NA | No Comments received | No Comments<br>received | No Comments<br>received |
| Total |  |   | 110.00 |    |    |                      |                         |                         |

<sup>\*</sup>CA certificate from Vaps & Company dated October 17, 2025

(ii) Progress in the objects -

|           |   | Source of information  |   |                                       | Amount utilised in Rs. Crore                            |  | ount utilised in Rs. Crore Unutilised amount in Rs. crore Monitoring Agency |      | Comments of the Board of Directors   |                              |                                 |
|-----------|---|--|---|---------------------------------------|---|--|---|------|--|------------------------------|---------------------------------|
| Sr.<br>No | Item<br>Head  | / certifications considered by Monitoring Agency for preparation of report | Amount as<br>proposed<br>in the Offer<br>Document<br>in Rs. Crore | Amount<br>received<br>in Rs.<br>Crore | As at<br>beginning<br>of the<br>quarter in<br>Rs. Crore | During<br>the<br>quarter<br>in<br>Rs.<br>Crore | At<br>the<br>end<br>of<br>the<br>quarter<br>in Rs.<br>Crore                 |      |  | Reasons<br>for idle<br>funds | Proposed<br>course of<br>action |
| 1         | Capital Expenditure for future expansion of existing products and other allied products as may be decided by the board within the | Chartered Accountant<br>certificate*, Bank<br>Statements,                  | 33.00   | 27.50                                 | 11.03   | 16.47  | 27.50   | 0.00 | Company has incurred Rs. 16.47 crores towards capital expenditure in the quarter ended September 30, 2025. | No<br>Comments<br>received   | No<br>Comments<br>received      |
|           | tentative timeline of the utilization   |  |   |                                       |   |  |   |      |  |                              |                                 |

CARE Ratings Limited
9th floor, C-001/A2, Berger Towers, Sector 16B, Gautam Budh Nagar, Uttar Pradesh -201301

Phone: +91-120-4452000

CIN-L67190MH1993PLC071691

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East),

Mumbai - 400 022 Phone: +91-22-6754 3456



|           | Source of information  |  |   |                                       | Amount utilised in Rs. Crore                            |  | Unutilised amount in Rs. crore                              | Comments of the<br>Monitoring Agency |   | nts of the<br>Directors      |                                 |
|-----------|--|--|---|---------------------------------------|---|--|---|--------------------------------------|---|------------------------------|---------------------------------|
| Sr.<br>No | Item<br>Head   | / certifications     considered by     Monitoring Agency     for preparation of         report | Amount as<br>proposed<br>in the Offer<br>Document<br>in Rs. Crore | Amount<br>received<br>in Rs.<br>Crore | As at<br>beginning<br>of the<br>quarter in<br>Rs. Crore | During<br>the<br>quarter<br>in<br>Rs.<br>Crore | At<br>the<br>end<br>of<br>the<br>quarter<br>in Rs.<br>Crore |                                      |   | Reasons<br>for idle<br>funds | Proposed<br>course of<br>action |
| 2         | Working Capital<br>for the business<br>operations post<br>expansion and<br>incidental thereto<br>for diversification<br>of products. | Chartered Accountant certificate*, Bank statements   | 77.00   |                                       | 0.00  | 0.00   | 0.00  |                                      | Nil for the quarter ended<br>September 30, 2025 | No<br>Comments<br>received   | No<br>Comments<br>received      |
| Total     |  | /ama 0. Camanani datad Oata  | 110.00@   | 27.50                                 | 11.03   | 16.47  | 27.50   | 0.00                                 |   | ,                            |                                 |

<sup>\*</sup>CA certificate from Vaps & Company dated October 17, 2025

(iii) Deployment of unutilized public issue proceeds:

| Sr. No. | Type of instrument and name of the entity invested in | Amount invested | Maturity date | Earning | Return on Investment (%) | Market Value as at the end of quarter |
|---------|---|-----------------|---------------|---------|--------------------------|---------------------------------------|
|         |   |                 | Nil           |         |                          |                                       |

(iv) Delay in implementation of the object(s) -

|   | Compl                     | etion Date                                     | Dolay (no. of days)            | Comments of t        | he Board of Directors     |
|---|---------------------------|--|--------------------------------|----------------------|---------------------------|
| Objects   | As per the offer document | Actual   | Delay (no. of days/<br>months) | Reason of delay      | Proposed course of action |
| Capital Expenditure for future expansion of existing products and other allied products as may be decided | -                         | Ongoing, Rs. 27.50 crores incurred till Q2FY26 | Not applicable                 | No Comments received | No Comments received      |

CARE Ratings Limited
9th floor, C-001/A2, Berger Towers, Sector 16B, Noida, Gautam Budh Nagar, Uttar Pradesh -201301

Phone: +91-120-4452000

CIN-L67190MH1993PLC071691

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East),

Mumbai - 400 022 Phone: +91-22-6754 3456

<sup>@</sup>Out of the total issue of Rs. 110.00 crores company has received Rs. 27.50 crores in Q1FY26 and there was no amount received during Q2FY26. It is yet to receive Rs.82.50 crores.



|  | Compl                     | etion Date | Delay (no. of days/ | Comments of the Board of Directors |                           |  |
|--|---------------------------|------------|---------------------|------------------------------------|---------------------------|--|
| Objects  | As per the offer document | Actual     | months)             | Reason of delay                    | Proposed course of action |  |
| by the board within the tentative timeline of the utilization  |                           |            |                     |                                    |                           |  |
| Working Capital for the business operations post expansion and incidental thereto for diversification of products. |                           | Ongoing    | Not applicable      | No Comments received               | No Comments received      |  |

# 3) Details of utilization of proceeds stated as General Corporate Purpose (GCP) amount in the offer document:

| Sr. No | Item Head^     | Amount in Rs. Crore | Source of information / certifications considered by<br>Monitoring Agency for preparation of report | Comments of Monitoring Agency | Comments of the Board of<br>Directors |  |
|--------|----------------|---------------------|---|-------------------------------|---------------------------------------|--|
| 1      | Not applicable | -                   | CA Certificate*   | Nil                           | No Comments received                  |  |
|        | Total          |                     |   |                               |                                       |  |

CARE Ratings Limited
9th floor, C-001/A2, Berger Towers, Sector 16B, Noida, Gautam Budh Nagar, Uttar Pradesh -201301

Phone: +91-120-4452000

CIN-L67190MH1993PLC071691

4th Floor, Godrej Coliseum, Somaiya Hospital Road, Off Eastern Express Highway, Sion (East), Mumbai - 400 022

Phone: +91-22-6754 3456

<sup>\*</sup> CA certificate from Vaps & Company dated October 17, 2025
^ Section from the offer document related to GCP: Not Applicable as GCP is not the defined object as per the Offer document and notice of issue.



## **Disclaimers to MA report:**

- a) This Report is prepared by CARE Ratings Ltd (hereinafter referred to as **"Monitoring Agency/MA"**). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.
- b) This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like statutory auditors (or from peer reviewed CA firms) appointed by the Issuer believed by it to be accurate and reliable.
- c) Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.
- d) The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.
- e) The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.